Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sylentis, a company focused on R&D of new drugs based on gene silencing (interference RNA, RNAi), has concluded SYL040012 Phase Ia clinical trial in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.
Subscribe to our email newsletter
Sylentis claimed that the trial result was positive. In the trial, the patients demonstrated local and systemic tolerance to SYL040012.
The trial’s endpoint was to determine the tolerance and safety of SYL040012 ophthalmic drops; it was administered to 30 healthy volunteers aged 18 to 33.
Sylentis said that the trial received the Spanish Medicines and Health Products Agency’s approval in June 2009.
In preclinical trials SYL040012 prevented the increase in intraocular pressure induced in the ocular hypertension model that was used.
Ocular tolerance studies showed positive results and demontrated local and systemic tolerance to the administration of SYL040012 in much larger doses than required for therapeutic effectiveness.
Going forward, Sylentis plans to initiate a Phase I/II clinical trial in patients with elevated intraocular pressure soon.